Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00020670 · ClinicalTrials.gov registry record · Early Phase 1
Vaccine Therapy in Treating Patients With Acute Lymphoblastic Leukemia
A Early Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 9
- Enrollment target
NCT00020670: Clinical Trial Early Phase 1 study, sponsored by Dana-Farber Cancer Institute.
NCT00020670 is a Early Phase 1 study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 9 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00020670, a Early Phase 1 study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The prognosis for children and adults with acute lymphoblastic leukemia (ALL) has improved significantly over the years. Nevertheless, patients who experience disease relapse or induction failure along with patients having unfavorable genetics \[t(4;11) or t(9;22)\] have dismal prognosis. For these patients, novel therapeutic approaches such as immunotherapy are needed. In this clinical trial, investigators evaluate whether it is feasible to make a vaccine from leukemia cells and whether this vaccine enables direct immunity against cancer cells in patients.
Primary Outcome
Vaccine preparation is a success if an adequate number of CD40 activated cells (at least 1 x 10\^8 cells) can be generated.
Interventions
- BIOLOGICAL CD 40
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2001-02-20 |
| Est. Completion | 2003-07-01 |
| Phase | Early Phase 1 |
Why NCT00020670 stopped before completion
NCT00020670 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 1 intervention - of which CD 40 is the first listed.
NCT00020670 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00020670 about?
NCT00020670 is a clinical study titled "Vaccine Therapy in Treating Patients With Acute Lymphoblastic Leukemia". The prognosis for children and adults with acute lymphoblastic leukemia (ALL) has improved significantly over the years. Nevertheless, patients who experience disease relapse or induction failure along with patients having unfavorable genetics \[t(4;11) or t(9;22)\] have dismal prognosis. For these ...
What is the current status of trial NCT00020670?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 9 participants. The study started on 2001-02-20. Estimated completion is 2003-07-01.
What interventions are being tested in trial NCT00020670?
The interventions under investigation include: CD 40 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00020670?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00020670's enrollment target sits among peer trials
9 1745th of 2000 higher than 219 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI